第4章 癌症治療上單株抗體的必要性

第5章 癌症單株抗體市場概要

第6章 癌症單株抗體市場動態

第7章 癌症單株抗體的開發中產品:代(階段)，適應症，企業，國別

第8章 已上市的癌症單株抗體:各適應症·各企業·各國

第9章 臨床實驗中斷·中止的單株抗體開發中產品:不同階段:各適應症·各企業·各國

未提出開發報告

中止的

退出市場的

中斷的

第10章 競爭環境

Abbvie

Amgen

Bayer HealthCare

Biogen Idec

Eli Lilly

Genmab

Gilead Sciences

GlaxoSmithKline

Novartis

Pfizer

Roche

Seattle Genetics

圖表一覽

目錄

Recent years have witnessed the emergence of monoclonal antibodies, which has
the potential to offer less toxic and more efficient therapeutic alternatives
for patients. Over the past decades, the researchers have increased their
learning about the human body's immune system, which has led to the
achievement of significant number of regulatory milestones during this period.
The use of mAbs for treating cancer has increased significantly. The rising
market availability of these agents has enabled the pharma companies to
develop novel combination approaches which have the capability to provide even
greater insight into the body's immune system so as to develop more efficient
mAbs.

A significant amount of research is being carried out currently to improve the
level of potency of monoclonal antibodies. Consequently, a relatively new
approach has been indentified in which the precision of targeting molecules
would be combined with the proved killing power of radiation or cytotoxic
chemotherapy which is referred to as payload to precise molecular carriers,
mostly monoclonal antibodies. However, still a lot of work needs to be done
in this arena.

Though the monoclonal antibodies have already emerged as significant part of
the treatment for many cancers, the use of these antibodies in other aspects
of cancer treatment is yet to be tapped. In this regard, research is currently
being undertaken to understand deeply the process and reason for cancer cells
being different from normal cells and the use of mAbs to exploit these
differences. This has led to the development of many newer forms of mAbs,
which are being attached to drugs or other substances thus making them more
powerful.

Additionally, the pharma companies are also researching on ways and means to
make these drugs more safe and effective. As an illustration, since mAbs are
proteins, there is a high chance that these antibodies could possibly make the
body's immune system react against them, which could result in many side
effects, and also destruction of the mAbs. The newly developed forms of mAbs
are a solution to this problem and are less likely to cause immune reactions.

It is expected that during the next decade, with the discovery and
introduction of new tumor-specific proteins, newer MAb targets would be
successfully identified for regulating tumor cell growth or inducing
apoptosis. Additionally, the changes in MAb would also allow for more
efficient radionuclide or cytotoxic MAb drug targeting or lead to more
efficient activation of host effector mechanisms which tend to lead to better
therapeutic antibodies. The future of mAbs for cancer continues to be
overflowing with huge potential as a result of an increasing number of new
discoveries and techniques. Inspite of advances being made in terms of
understanding of the complexities of the human cells there is still
significant work which needs to be done.